June 10, 2022

Khaled Mohamed
Medexus Pharma, Inc.
29 N. Wacker Drive, Suite 704
Chicago, IL 60606

Sent via email to: khaled.mohamed@medexus.com

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drug determine whether the Reference Listed Drug (RLD), ARISTOSPAN® (triamcinolone hexacetonide injectable suspension, USP), 20 mg/mL, NDA 016466 held by Sandoz Inc., has been voluntarily withdrawn from the commercial market or withdrawn from sale for safety or effectiveness reasons was received and processed under CFR 10.30 by this office on 06/09/2022.

It was assigned docket number FDA-2022-P-1104. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen P. Malvin -S
Digitally signed by Karen P. Malvin -S
Date: 2022.06.13 08:01:32 -04'00'

Karen Malvin
Acting Director
Dockets Management Staff
FDA/Office of Operations (OO)